查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493188

組合藥物市場規模、佔有率、趨勢分析報告：依產品、地區、細分市場預測，2024-2030

Drug Device Combination Products Market Size, Share & Trends Analysis Report By Product (Transdermal Patches, Infusion Pumps, Inhalers, Drug Eluting Stents), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

組合藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球組合藥物市場規模將達2,518.7億美元，2024年至2030年複合年成長率為9.0%。

由於與微創技術相關的患者治療效果的改善，需求不斷成長，這是該市場的一個有影響力的驅動力。這些設備有助於早期診斷並縮短大多數外科手術的治療時間。需求增加的另一個原因是這些設備所提供的疼痛最小化、成本效率提高、安全性提高、療效提高、恢復更快、住院時間縮短。

醫療保健監管機構擴大執行明確的上市前核准通訊協定，預計將支持製造商獲得其產品的核准。最近，美國FDA採用了精益管理流程映射方法，以創建一個更具凝聚力、精簡、系統和協作的系統來審查上述產品。這些當局發布的安全指南和建議預計將在未來增加這些產品的採用，從而促進其在預測期內的整體成長。

由於藥物在體內非預期部位吸收而導致的與治療藥物相關的嚴重副作用和藥物交互作用預計將引發對標靶治療的需求，從而推動對藥物-器械組合的需求。例如，連續施用左旋多巴會導致長期併發症，例如運動波動、運動障礙、嚴重的代謝變化和神經毒性。這些因素使得臨床迫切需要採用基於標靶治療的替代方案，例如藥物-器械組合產品。

組合藥物市場報告亮點

  • 由於需要長期治療的疾病的自我給藥需求不斷增加，經皮貼片在 2023 年的產品市場佔有率中佔據主導地位。
  • 從2023年的地區佔有率來看，北美地區所佔佔有率最大，超過41.31%，因為該地區的主要企業正在進行廣泛的新產品開發活動。
  • 由於醫療保健支出的增加以及醫生對這些產品益處的意識層級的提高，預計亞太地區未來幾年將以有利的速度成長。
  • 主要市場參與者正在採取各種策略，例如新產品發布和銷售合作夥伴關係，以提高市場滲透率。
  • 由於較高的營運成本、嚴格的法律規範和資本要求，預計新進入者的威脅較低。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 複方藥物市場的變數與趨勢

  • 市場體系展望
  • 市場動態
    • 市場促進因素影響分析
    • 市場限制因素影響分析
    • 市場機會影響分析
  • 產業分析工具
    • 波特的分析
    • 宏觀經濟分析

第4章 組合藥物市場：產品分析

  • 2023 年產品變化分析與市場佔有率
  • 依產品
  • 點滴幫浦
  • 整形外科組合產品
  • 動態治療儀
  • 經皮吸收貼片
  • 藥物釋放型支架
  • 創傷護理產品
  • 吸入
  • 抗菌導管
  • 其他

第5章 組合藥市場：區域估計與趨勢分析

  • 組合藥物市場：區域前景
  • 北美洲
    • 2018-2030 年北美組合藥物市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲組合藥物市場估計與預測
    • 德國
    • 英國
    • 法國
  • 亞太地區
    • 2018-2030 年亞太地區複方藥物市場估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲組合藥物市場估計與預測
    • 巴西
    • 墨西哥
  • 中東/非洲
    • 2018-2030年中東和非洲組合藥物市場估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭分析

  • 公司分類
  • 參與者概覽
  • 財務績效
  • 產品基準
  • 企業市場：定位分析
  • 策略規劃
    • 併購
    • 夥伴關係與協作
    • 產品上市和監管核准
    • 擴張
  • 公司簡介
    • Abbott
    • Terumo Medical Corporation
    • Stryker
    • Viatris Inc.
    • Medtronic
    • Boston Scientific Corporation
    • Novartis AG
    • Becton
    • Dickinson and company
    • Teleflex Incorporation

第7章 分析師觀點

Product Code: GVR-1-68038-260-0

Drug Device Combination Products Market Growth & Trends:

The global drug device combination products market size is expected to reach USD 251.87 billion by 2030, registering a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduce treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.

Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.

Drug Device Combination Products Market Report Highlights:

  • Transdermal patch held the dominant share by product in 2023 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
  • North America held the largest share of over 41.31% in 2023 in terms of region owing to extensive new product development activities conducted by prominent players across this region
  • Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
  • Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration
  • High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
  • 1.2. Market Definition
    • 1.2.1. Product
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objectives 1
    • 1.10.2. Objectives 2
    • 1.10.3. Objectives 3

Chapter 2. Executive Summary

  • 2.1. Market Snapshot (Regional)
  • 2.2. Segment Snapshot (Product)
  • 2.3. Competitive Landscape

Chapter 3. Drug Device Combination Products Market Variables, and Trends

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver impact analysis
      • 3.2.1.1. Increasing demand for minimally invasive drug delivery devices
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Increasing prevalence of chronic diseases
    • 3.2.2. Market Restraint Impact Analysis
      • 3.2.2.1. High cost associated with drug device combination products
      • 3.2.2.2. Technical challenges in drug delivery
      • 3.2.2.3. Increasing prevalence of chronic diseases
    • 3.2.3. Market Opportunity Impact Analysis
      • 3.2.3.1. Growing adherence rate
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's analysis
    • 3.3.2. Macroeconomics analysis

Chapter 4. Drug Device Combination Product Market: Product Analysis

  • 4.1. Product Movement Analysis & Market Share, 2023
  • 4.2. Drug Device Combination Products Market: Estimates & Forecast, By Product (USD Billion)
    • 4.2.1. Infusion Pumps
      • 4.2.1.1. Infusion pumps market, 2018 - 2030 (USD Million)
      • 4.2.1.2. Volumetric
      • 4.2.1.2.1. Volumetric market, 2018 - 2030 (USD Million)
      • 4.2.1.3. Disposables
      • 4.2.1.3.1. Disposables market, 2018 - 2030 (USD Million)
      • 4.2.1.4. Syringes
      • 4.2.1.4.1. Syringes market, 2018 - 2030 (USD Million)
      • 4.2.1.5. Ambulatory
      • 4.2.1.5.1. Ambulatory market, 2018 - 2030 (USD Million)
      • 4.2.1.6. Implantable
      • 4.2.1.6.1. Implantable market, 2018 - 2030 (USD Million)
      • 4.2.1.7. Insulin
      • 4.2.1.7.1. Insulin market, 2018 - 2030 (USD Million)
    • 4.2.2. Orthopedic combination products
      • 4.2.2.1. Orthopedic combination product market, 2018 - 2030 (USD Million)
      • 4.2.2.2. Bone Graft Implants
      • 4.2.2.2.1. Bone graft implant market, 2018 - 2030 (USD Million)
      • 4.2.2.3. Antibiotic Bone Cement
      • 4.2.2.3.1. Antibiotic bone cement market, 2018 - 2030 (USD Million)
    • 4.2.3. Photodynamics therapy devices
      • 4.2.3.1. Photodynamics therapy devices market, 2018 - 2030 (USD Million)
    • 4.2.4. Transdermal patches
      • 4.2.4.1. Transdermal patches market, 2018 - 2030 (USD Million)
    • 4.2.5. Drug eluting stents
      • 4.2.5.1. Drug eluting stents market, 2018 - 2030 (USD Million)
      • 4.2.5.2. Coronary Stents
      • 4.2.5.2.1. Coronary Stents market, 2018 - 2030 (USD Million)
      • 4.2.5.3. Peripheral vascular stents
      • 4.2.5.3.1. Peripheral vascular stents market, 2018 - 2030 (USD Million)
    • 4.2.6. Wound care products
      • 4.2.6.1. Wound care product market, 2018 - 2030 (USD Million)
    • 4.2.7. Inhalers
      • 4.2.7.1. Inhalers market, 2018 - 2030 (USD Million)
      • 4.2.7.2. Dry powder
      • 4.2.7.2.1. Dry powder market, 2018 - 2030 (USD Million)
      • 4.2.7.3. Nebulizers
      • 4.2.7.3.1. Nebulizers market, 2018 - 2030 (USD Million)
      • 4.2.7.4. Metered Dose
      • 4.2.7.4.1. Metered Dose market, 2018 - 2030 (USD Million)
    • 4.2.8. Antimicrobial catheters
      • 4.2.8.1. Antimicrobial catheters market, 2018 - 2030 (USD Million)
      • 4.2.8.2. Urological
      • 4.2.8.2.1. Urological market, 2018 - 2030 (USD Million)
      • 4.2.8.3. Cardiovascular
      • 4.2.8.3.1. Cardiovascular market, 2018 - 2030 (USD Million)
      • 4.2.8.4. Others
      • 4.2.8.4.1. Others market, 2018 - 2030 (USD Million)
    • 4.2.9. Others
      • 4.2.9.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Drug Device Combination Products Market: Regional Estimates & Trend Analysis

  • 5.1. Drug Device Combination Products Market: Regional Outlook
  • 5.2. North America
    • 5.2.1. North America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. Key country dynamics
      • 5.2.2.2. Competitive scenario
      • 5.2.2.3. Regulatory scenario
      • 5.2.2.4. Reimbursement scenario
      • 5.2.2.5. U.S. drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key country dynamics
      • 5.2.3.2. Competitive scenario
      • 5.2.3.3. Regulatory scenario
      • 5.2.3.4. Reimbursement scenario
      • 5.2.3.5. Canada drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.2. Germany
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Competitive scenario
      • 5.3.2.3. Regulatory scenario
      • 5.3.2.4. Reimbursement scenario
      • 5.3.2.5. Germany drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. UK
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Competitive scenario
      • 5.3.3.3. Regulatory scenario
      • 5.3.3.4. Reimbursement scenario
      • 5.3.3.5. UK drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. Key country dynamics
      • 5.3.4.2. Competitive scenario
      • 5.3.4.3. Regulatory scenario
      • 5.3.4.4. Reimbursement scenario
      • 5.3.4.5. France drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Competitive scenario
      • 5.4.2.3. Regulatory scenario
      • 5.4.2.4. Reimbursement scenario
      • 5.4.2.5. Japan drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Competitive scenario
      • 5.4.3.3. Regulatory scenario
      • 5.4.3.4. Reimbursement scenario
      • 5.4.3.5. China drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Competitive scenario
      • 5.4.4.3. Regulatory scenario
      • 5.4.4.4. Reimbursement scenario
      • 5.4.4.5. India drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Australia
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Competitive scenario
      • 5.4.5.3. Regulatory scenario
      • 5.4.5.4. Reimbursement scenario
      • 5.4.5.5. Australia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. South Korea
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Competitive scenario
      • 5.4.6.3. Regulatory scenario
      • 5.4.6.4. Reimbursement scenario
      • 5.4.6.5. South Korea drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Competitive scenario
      • 5.5.2.3. Regulatory scenario
      • 5.5.2.4. Reimbursement scenario
      • 5.5.2.5. Brazil drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Mexico
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Competitive scenario
      • 5.5.3.3. Regulatory scenario
      • 5.5.3.4. Reimbursement scenario
      • 5.5.3.5. Mexico drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East & Africa
    • 5.6.1. Middle East & Africa drug device combination products market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.6.2. South Africa
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Competitive scenario
      • 5.6.2.3. Regulatory scenario
      • 5.6.2.4. Reimbursement scenario
      • 5.6.2.5. South Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Competitive scenario
      • 5.6.3.3. Regulatory scenario
      • 5.6.3.4. Reimbursement scenario
      • 5.6.3.5. Saudi Arabia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. UAE
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Competitive scenario
      • 5.6.4.3. Regulatory scenario
      • 5.6.4.4. Reimbursement scenario
      • 5.6.4.5. UAE drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Competitive scenario
      • 5.6.5.3. Regulatory scenario
      • 5.6.5.4. Reimbursement scenario
      • 5.6.5.5. Kuwait drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Analysis

  • 6.1. Company Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Performance
  • 6.4. Product Benchmarking
  • 6.5. Company Market: Position Analysis
  • 6.6. Strategy Mapping
    • 6.6.1. Mergers & acquisitions
    • 6.6.2. Partnerships & collaborations
    • 6.6.3. Product launch & regulatory approval
    • 6.6.4. Expansion
  • 6.7. Company Profiles
    • 6.7.1. Abbott
      • 6.7.1.1. Company Overview
      • 6.7.1.2. Financial Performing
      • 6.7.1.3. Product Benchmarking
      • 6.7.1.4. Strategic Initiatives
    • 6.7.2. Terumo Medical Corporation
      • 6.7.2.1. Company Overview
      • 6.7.2.2. Financial Performing
      • 6.7.2.3. Product Benchmarking
      • 6.7.2.4. Strategic Initiatives
    • 6.7.3. Stryker
      • 6.7.3.1. Company Overview
      • 6.7.3.2. Financial Performing
      • 6.7.3.3. Product Benchmarking
      • 6.7.3.4. Strategic Initiatives
    • 6.7.4. Viatris Inc.
      • 6.7.4.1. Company Overview
      • 6.7.4.2. Financial Performing
      • 6.7.4.3. Product Benchmarking
      • 6.7.4.4. Strategic Initiatives
    • 6.7.5. Medtronic
      • 6.7.5.1. Company Overview
      • 6.7.5.2. Financial Performing
      • 6.7.5.3. Product Benchmarking
      • 6.7.5.4. Strategic Initiatives
    • 6.7.6. Boston Scientific Corporation
      • 6.7.6.1. Company Overview
      • 6.7.6.2. Financial Performing
      • 6.7.6.3. Product Benchmarking
      • 6.7.6.4. Strategic Initiatives
    • 6.7.7. Novartis AG
      • 6.7.7.1. Company Overview
      • 6.7.7.2. Financial Performing
      • 6.7.7.3. Product Benchmarking
      • 6.7.7.4. Strategic Initiatives
    • 6.7.8. Becton
      • 6.7.8.1. Company Overview
      • 6.7.8.2. Financial Performing
      • 6.7.8.3. Product Benchmarking
      • 6.7.8.4. Strategic Initiatives
    • 6.7.9. Dickinson and company
      • 6.7.9.1. Company Overview
      • 6.7.9.2. Financial Performing
      • 6.7.9.3. Product Benchmarking
      • 6.7.9.4. Strategic Initiatives
    • 6.7.10. Teleflex Incorporation
      • 6.7.10.1. Company Overview
      • 6.7.10.2. Financial Performing
      • 6.7.10.3. Product Benchmarking
      • 6.7.10.4. Strategic Initiatives

Chapter 7. Analysis Perspective

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Drug device combination products market revenue estimates and forecast, by product, 2018 - 2030 (USD Billion)
  • Table 4 U.S. regulatory procedure for medical devices
  • Table 5 Canada regulatory procedure for medical devices
  • Table 6 Classification of medical devices

List of Figures

  • Fig. 1 Drug device combination products market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot, USD Million
  • Fig. 9 Segment snapshot (Product)
  • Fig. 10 Competitive landscape
  • Fig. 11 Drug delivery devices and drug device combination products market value, 2023 (USD million)
  • Fig. 12 Drug device combination products market dynamics
  • Fig. 13 Diabetes around the world in 2021, (Million)
  • Fig. 14 Estimated number of U.S. hospital hip and knee replacement procedures: (2021 - 2022)
  • Fig. 15 Drug device combination products market: PORTER's analysis
  • Fig. 16 Drug device combination products market: PESTEL analysis
  • Fig. 17 Drug device combination product market: Product outlook and key takeaways
  • Fig. 18 Drug device combination products market, by product: Market share, 2023 & 2030
  • Fig. 19 Infusion pumps market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Volumetric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Disposables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Syringes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Ambulatory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Implantable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Orthopedic combination products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Bone graft implants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Antibiotic bone cement market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Photodynamic therapy devices market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Transdermal patches market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Drug eluting stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Coronary stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Peripheral vascular stents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Wound care products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Inhalers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Dry powder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Nebulizers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Metered dose market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Antimicrobial catheters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Urological market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Drug device combination products market revenue, by region, 2023 & 2030 (USD Billion)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Reimbursement procurement process
  • Fig. 49 US drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Europe drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 France drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Reimbursement procurement process
  • Fig. 62 Japan drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 China drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 India drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Australia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 South Korea drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Brazil drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Mexico drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Middle East & Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 South Africa drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Saudi Arabia drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 UAE drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Kuwait drug device combination products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategy mapping